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OBJECTIVE: The objective of this selective evidence based medicine review is to determine 
whether or not “Are PRP injections effective at decreasing chronic low back pain in adults?” 
 
STUDY DESIGN: Systematic review of two randomized control trials and one prospective 
clinical evaluation written in English, published after the year 2012.   
 
DATA SOURCES:  All three articles were found in peer review journals published via PubMed 
Database.  
 
OUTCOME MEASURED: The primary outcome measured in each study is self-reported pain 
at baseline and 4 weeks following injection of PRP or the comparison. The visual analog scale 
and a generic numeric rating scale were used to measure pain.  
 
RESULTS: 1 of the 3 studies found PRP injections to be statistically effective at decreasing low 
back pain in adults at the time period assessed. Wu et al found that, at 4 weeks post injection, 
pain scores on a scale of 0 to 10 were on average 3.84 points less when compared to baseline 
scores (p<0.05) and were significantly lower at all other time points as well (Pain physician. 
2016;19(8):617. https://www.ncbi.nlm.nih.gov/pubmed/27906940). Singla et al found no 
significant difference in pain levels at 4 weeks post injection when compared to the steroid 
control group but found a 75% reduction in VAS at 4 weeks when compared to baseline scores 
(Pain practice: the official journal of World Institute of Pain. 2017;17(6):782-791. 
https://www.ncbi.nlm.nih.gov/pubmed/27677100. doi: 10.1111/papr. 12526). The Tuakli-
Wosornu et al study also revealed no significant difference in pain at 4 weeks when compared to 
baseline (p=0.215), but participants did have significant improvement regarding pain, function, 
and patient satisfaction over 8 weeks (PM R. 2016;8(1):1-10. 
https://ezproxy.pcom.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=jlh
&AN=112177067&site=eds-live&scope=site. doi: 10.1016/ j.pmrj.2015.08.010).   
 
CONCLUSIONS: This review finds conflicting evidence that PRP injections are more effective 
than other treatment for chronic low back pain. The 2 RCTs did not show significant decrease in 
pain at the 4 week follow up time assessed, and the remaining study had severe limitations. 
Regardless, all three studies did show statistically significant improvement by the end of each 
study, so this review finds stronger evidence to support PRP injections for adjunctive use in 
adults with chronic low back pain.  
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An estimated 84% of adults have low back pain at some point in their lives.1 Most cases 
are self-limiting and resolve within 6 weeks.1 Chronic low back pain is defined as pain persisting 
longer than 12 weeks.2 The cause is often multifactorial and difficult to diagnose. Intervertebral 
discs are the origin of 40% of reported back pain and are the largest avascular structure in the 
human body, contributing to the disc’s inability to regenerate and heal.3 Facet joints are synovial 
joints of the spine that, with overuse and injury, can degenerate and cause a release of 
inflammatory mediators, capsular stretch, entrapment of synovial villi between articular surfaces, 
and nerve impingement by osteophytes.4 Nearly 15-52% of patients have low back pain caused 
by lumbar facet joint syndrome.4 The sacroiliac joint has been found to be the primary point of 
pain in 10% to 27% of adults with chronic low back pain, usually owing to injury.5 Back injuries 
are more common in patients younger than 45, and disc disorders increase in frequency as the 
population ages.6  
Secondary only to skin disorders, low back pain is one of the most common reasons 
people visit their primary care provider. In 2013 there were an estimated 62 million visits to 
hospitals, emergency departments, outpatient clinics, and physician offices,6 and costs estimated 
at $87.6 billion make low back pain the third largest condition of health care spending.7 These 
statistics do not include visits to chiropractors and physical therapists.  
For patients with chronic low back pain, management can be a lengthy and trial-by-error 
process. Initially, patients are encouraged to utilize nontherapeutic treatments such as stretching, 
exercise, and heat application, as well as psychological therapies such as CBT and biofeedback.1 
Adjunctive therapies for short-term management of symptoms include spinal manipulation, 
acupuncture, or massage.1 For more severe pain symptoms, pharmacologic therapy is used along 
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with nonpharmacologic measures.1 Non-steroidal anti-inflammatory drugs (NSAIDs) are first 
line, and if contraindicated acetaminophen is recommended.1 If these are ineffective, duloxetine, 
tramadol, cyclobenzaprine, and epidural injections may be utilized.1 Neuropathic pain can be 
treated with alpha-2-delta ligands such as gabapentin.7 Surgery, although unlikely to cure low 
back pain, can improve pain levels. Surgical indications include cauda equina syndrome, cancer, 
infection, severe spinal deformity, or persistent morbidity despite treatment with conservative 
measures for 6 months.7 
 Although the above treatments have some proven efficacy when compared to 
placebo in clinical trials, chronic low back pain continues to decrease the quality of life for 
millions of Americans. Platelet rich plasma (PRP) has been shown to be effective in treating 
many different musculoskeletal disorders and may be used as combination therapy with the 
above treatments, leading to improvement in quality of life. PRP consists of a high concentration 
of platelets derived from the patient’s own peripheral venous blood. PRP is composed of 
bioactive proteins that influence the healing of tendons, ligaments, muscles, and bones; as well 
as growth factors and cytokines including platelet-derived growth factor, transforming growth 
factor-B, fibroblast growth factor, insulin-like growth factor 1, connective tissue growth factor, 
and epidermal growth factor.4 These components work to promote cell proliferation, matrix 
regeneration, and angiogenesis. Growth factors and cytokines injected at a high concentration 
directly at the site of collagen injury or degeneration can act as humoral mediators to induce the 
natural healing cascade. In addition, they produce an anti-inflammatory effect and lab studies 
indicate that PRP possesses antimicrobial properties that contribute to a decreased risk of 
infection.5 PRP has been shown in previous studies to be effective at reducing pain and 
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functional disability in conditions such as tennis elbow, knee osteoarthritis, achilles 
tendinopathy, and chronic patellar tendinosis.5  
Physician assistants are likely to encounter patients with chronic low back pain regardless 
of their chosen specialty. Given the method of administration, affordability, and accessibility, 
PRP is a treatment option deserving closer consideration.  
OBJECTIVE  
 
The objective of this selective evidence based medicine review is to determine whether or 
not “Are PRP injections effective at decreasing chronic low back pain in adults?” 
METHODS 
 
This review evaluates three peer-reviewed articles that assess the efficacy of PRP in 
reducing chronic low back pain. Two studies used control injections for comparison: contrast3 
and methylprednisolone with lidocaine and saline.5 The three studies include a prospective 
clinical trial; a prospective, double blind randomized control study; and a prospective 
randomized open blinded end point study that have not been previously used in a systematic 
review or meta-analysis. Participants were 18 years of age or older with diagnosed chronic low 
back pain. See Table 1 for specific inclusion and exclusion criteria for each individual study. 
Pain intensity was assessed before and after administration of PRP or the control agent at 
different time intervals. Each article reported pain evaluated at different intervals and reported 
pain accordingly. This paper will focus on the pain reports collected prior to intervention and 4 
weeks post-injection. The statistics used to evaluate pain intensity are mean pain scores with 
standard deviation, paired t-test, and p-values.  
Key words used to search for the studies were “low back OR lumbar”, and “PRP OR 
platelet rich plasma”. Each article was published in English and found via PubMed database with 
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the inclusion criteria of publication after the year 2012 and randomized controlled trials. Only 
two randomized controlled trials were identified that matched these criteria, so the prospective 
clinic evaluation was selected based on its relevance to the objective. All three articles were 
selected based on patient oriented outcomes. Exclusion criteria included patients under the age of 
18 and those with acute low back pain.  
TABLE 1: Demographics & Characteristics of Included Studies  




Inclusion Criteria  Exclusion Criteria  W/D Interventions 
Singla1 
(2017) 
RCT  40 18-65 Patients >18 with 
chronic low back pain 
of moderate intensity 
for >3 months; 
unilateral SIJ pathology 
on XR, MRI or nuclear 
scan with 3 or more + 
provocative tests.  
Systemic or 
localized infection; 
spinal path that 
might impede 







to medications used; 
narcotic use, CI 
pertaining to the use 
of platelet 
concentrate.  
0 3mL of PRP 









RCT 47 >18 
yrs 
Refractory low back 
pain for >6 months; 
failure of conservative 
treatment; maintained 
intervertebral disk 
height of at least 50%; 
disk protrusion <5mm 
on MRI or CT; 
concordant pain on 
diskography; presence 
of a grade 3 or 4 
annular fissure; absent 
CI 





systemic or local 














discordant pain on 
diskography; 
presence of grade 5 
















19 38-62 Continuous or 
intermittent low back 
pain; local or paraspinal 
pain with or without 
radiation, increase of 
pain on flexion, 
rotation, or lateral 
bending, absence of 
neuro deficit, XR 
showing findings of 
lumbar facet joint 
degenerative changes  
Radicular neuro 
complaints or with 
evident disc 
herniations, prior 
surgery on the spine, 
intolerance of local 
anesthesia and 
contrast media  












OUTCOMES MEASURED  
 
The outcome measured in all three studies was the self-reported pain score of patients 4 
weeks after PRP injection, evaluated using the Visual Analog Scale (VAS) or Numeric Rating 
Scale (NRS). Both require the patient to rate their pain based on a 0 to 10 scale, with 0 being no 
pain and 10 being the worst pain imaginable.  
RESULTS  
 
 The prospective clinical evaluation by Wu et al included 8 men and 11 women with 
diagnosed lumbar facet joint pain who failed other interventions for at least 3 months prior to the 
study.4 Exclusion criteria included evident disc herniations and prior surgery, because these were 
identified as independent variables that affect pain relief after intra-articular facet joint 
injections.4 A CBC was performed on the patient’s peripheral blood before treatment and on the 
centrifuged PRP to ensure the platelet concentration in the PRP was about 4 to 5 times greater 
than that in the native peripheral blood. Patients were injected with approximately 1-2 mL of 
autologous PRP under fluoroscopy by a spine surgeon. There was no control injection group. No 
complications were observed throughout the procedures.4 Participants were instructed to rest and 
not to bend at the waist for one week. The results state that patients were given pain relief 
information and that “there was no anti-inflammatory treatment for patients during the 3 month 
follow-up period”, suggesting that patients could not take NSAIDs at home.4 The VAS was 
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conducted immediately following treatment and at 1 week, 1 month, 2 months, and 3 months 
post-procedure. The mean VAS scores for low back pain at rest were 7.05 before treatment and 
3.21 at 4 weeks (Table 2).4 A p-value of < 0.05 was calculated using the SPSS version 19.0 
program.4  
Table 2: Mean VAS Pain Scores at baseline and 4 weeks in Wu et al  
 Baseline  4 weeks post-op 
Mean  7.05 3.21 
P-value <0.05 
 
 Singla et al conducted a prospective randomized open blinded end point study that 
included 40 patients with chronic low back pain who were previously diagnosed with sacroiliac 
joint (SIJ) pathology.5 Patients had unilateral SIJ pathology on imaging with baseline VAS 
scores of greater than 3 for at least 3 months.5 Patients on greater than 60 mg of morphine 
equivalent doses of opioids were excluded due to their altered pain responses. The participants 
were allocated into 2 groups randomly by computer-generated numbers and the sequence was 
placed into sealed, opaque envelopes. Both the patients and investigators were blinded to the 
injectant given at the time of the procedure. There were no significant differences in the baseline 
parameters between the two groups. Under guidance of ultrasound, the comparison group (Group 
S) received 1.5 mL of methylprednisolone with 1.5 mL of 2% lidocaine and 0.5 mL of saline 
while the treatment group (Group P) received 3 mL of PRP with 0.5 mL of calcium chloride.5 
There were no major complications.5 The mean platelet content in the PRP was 2.94 + 1.43.5 All 
pain medication including NSAIDs were discontinued for the duration of the study, but those 
with diagnosed ankylosing spondylitis continued Sulfasalazine therapy. Patients were followed 
up at 2 weeks, 4 weeks, 6 weeks, and 3 months for assessment of pain intensity using the VAS. 
The percent change in score from baseline calculation formula was provided. Data was compared 
between the 2 groups using the Mann-Whitney U-test, and the follow up VAS scores were 
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compared to baseline with post hoc analysis using Bonferroni correction.5 All patients were 
analyzed in the groups to which they were randomized, and none were lost to follow up. The 
median VAS scores for Group P were 7.5 and 1.5 at pre-injection and 4 weeks, respectively.5 
The median VAS score for Group S went from 6 pre-injection down to 3 at 4 weeks.5 According 
to the calculated p-values, there was no statistically significant difference between groups at 
either time period. At 4 weeks, 75% of patients in Group P and 70% of patients in Group S had a 
reduction in VAS > 50%, with a p-value of 0.723.5 Therefore, there was no significant difference 
in patients having > 50% reduction in VAS score at 4 weeks among the two groups.5 
Table 3: Median VAS Pain Scores at baseline and 4 weeks in Singla et al  





Median (Interquartile Range) 
at baseline  
7.5 (5-8) 6 (5-7) 0.132 
Median (Interquartile Range) 
at 4 weeks  
1.5 (1-3) 3 (2-4) 0.054 
Reduction in VAS at 4 weeks  75% (15) 70% (14) 0.723 
 
The randomized controlled study performed by Tuakli-Wosornu et al included 47 
participants with chronic axial low back pain, diagnosed via discography.3 A total of 109 
participants were assessed for eligibility from 2009 to 2013 at an academic outpatient spine 
practice. Fifty-eight were chosen and randomized for inclusion into the study. After discography, 
7 were disqualified based on exclusion criteria, 3 failed to maintain inclusion and exclusion 
criteria throughout, and 1 was lost to follow up.3 Notable exclusion criteria include disk 
protrusion >5 mm because targeted annular therapy would likely be to no avail, and grade V 
annular fissures because the injectate would likely flow out of the disk into the epidural space, 
lessening the opportunity for the PRP to have an effect.3  
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About 2 weeks prior to treatment baseline blood samples were taken to assess blood 
counts, ESR, and PT/INR to ensure they were within normal limits. Randomization was 
performed by an independent observer who drew cards from a sealed envelope to form a 
treatment and control group with a 2:1 ratio, respectively. There was a significantly greater 
number of females randomized to the control group than the treatment group, but other 
demographics were not significantly different.3 During injection of 1-2 mL of either PRP or a 
contrast agent, the syringe was covered with an opaque sleeve to ensure that contents were not 
visible to the physician or the patient. There were no reported complications.3 All participants 
were followed with questionnaires at designated time points for one year, and a subset was 
followed for up to 2 years. If a participant did not meet a minimal clinically significant outcome, 
they were unblinded at 8 weeks and offered intradiscal PRP if they were part of the control 
group. The NRS is commonly presented as a 100 mm horizontal line on which pain intensity is 
labeled from 0 to 10. Differences in mean PRP group scores at follow up time points compared 
with those at baseline were assessed using paired t-tests. Measures of the association between 
groups were calculated using odds ratios with observed level of significance determined by 
Pearson X2 test. Mean NRS score at baseline was 4.61 and 4.74 for the control and PRP groups, 
respectively.3 At 4 weeks, mean NRS score was still 4.61 for the control group and dropped to 
4.0 for the PRP group.3 The p-value of 0.157, however, reveals an insignificant change between 
the two groups. 
Table 4: Median VAS Pain Scores at baseline and 4 weeks in Tuakli-Wosorni et al  




Mean + SD at baseline 4.74 + 2.21 4.61 + 2.21 
Mean + SD at 4 weeks  4.00 + 2.21 4.61 + 2.21 
P-value  0.215 0.157 
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The safety of sterile PRP injections was revealed throughout all three studies based on the 
lack of serious complications. Singla et al found that pain and stiffness post injection was higher 
in Group P when compared with Group S, but the symptoms were transient, local, and mild in 
nature.5 These symptoms are thought to be due to the stimulation of the body’s natural response 
to inflammatory mediators rather than the injection technique.5 
Table 5: Adverse Events Reported in PRP Groups 
Study PRP Group Size Adverse Event 
 
Singla et al 4 
 
20 
Post injection pain and stiffness (n=9) 
Chest pain and difficulty breathing (n=1) 
Contralateral pain (n=1) 
 
DISCUSSION  
 Wu et al found that participants had an average decrease of almost 4 points in their pain 
score rating 4 weeks after PRP injection.4 Pain scores improved even further by the end of the 3 
month follow up period, supporting the effectiveness of PRP for chronic low back pain. 
However, lack of comparison with a control group weakens the validity of this study.  
In the Singla et al study Group S had a significant increase in pain scores at 3 months as 
compared to 2 and 4 weeks, lending to the short-term action of steroids.5 This demonstrates that 
anti-inflammatory changes alone are not enough to reduce pain and disability long-term in 
patients with SIJ pain. The addition of growth factors enhances the biologic environment and 
improves tissue homeostasis. Although the findings were not significant at 4 weeks, the 
difference in VAS scores was significantly lower in Group P than Group S at 6 weeks and 3 
months.5 
Results of the Tuakli-Wosornu et al study revealed no statistically significant 
improvement in current pain at 4 weeks post injection when compared with controls.4 However, 
over the 8 weeks of follow up there were significant improvements in other measured outcomes: 
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best pain, function, and patient satisfaction. Furthermore, those who received PRP reported an 
improvement in function through at least one year of follow up.4  
Disadvantages of PRP include the variance of composition from subject to subject and 
possibly a small amount of growth factors.3 Two of the three studies performed cell content 
analysis on the PRP samples, ensuring uniformity and controlling for differences in quality of the 
treatment.4,5 All 3 studies had limitations in common including a relatively low number of 
participants, making it difficult to apply the results to the general population. None of the studies 
reviewed post procedure imaging to assess the effect that PRP had on the individual disease 
processes. Doing so would allow for determination of the best candidates for this procedure. 
The Wu et al study had many limitations due to the small sample size, lack of a control 
group, minimal follow up time of just 3 months, and lack of follow up imaging.4 There was a 
complete lack of information about allowed use of other pain relievers. No labs were completed 
and only subjective evidence was taken into consideration.  
Singla et al had an important strength unique to all the studies: they controlled the use of 
all other pain medication, including NSAIDs, throughout the study.5 Additionally, PRP was 
injected under ultrasound guidance, improving accuracy and limiting radiation exposure. 
Limitations of this study included a wide variability in the platelet count of PRP, short follow up 
time, and they allowed the continued use of sulfasalazine in participants who were diagnosed 
with ankylosing sponydlitis.5  
 The double-blind, randomized, controlled trial design, lengthy and rigorous selection 
process for participants, and long-term data were among the strengths of the Tuakli-Wosornu et 
al study.3 A limitation was the short follow up time of only 8 weeks for the control group. There 
was no data collection on the cell counts or biochemical analysis of the PRP used in this study.  
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CONCLUSION 
Steroids and other current treatment recommendations have been shown to offer short 
term relief of low back pain, but there is still a need to investigate long-lasting treatments that 
address the disease process itself. This review evaluated relief of low back pain 4 weeks after 
PRP injection and found that 2 of the 3 studies showed no statistically significant improvement 
vs the control group,3,5 and the third has substantial limitations discrediting validity.4 However, 
each study demonstrated improvement of pain after PRP injection in comparison with the 
baseline pain rating, and although this is not statistically significant it could still be clinically 
significant. This leads to the conclusion that PRP injections are effective at decreasing chronic 
low back pain in adults. PRP resolves the concern of long-term adverse effects of continuous 
intra-articular steroid injection and appears to have longer lasting benefits.5  
Future studies should combine the strengths of the studies evaluated in this review. The 
use of adjunctive pain medication should be restricted to offer better control. The studies should 
be designed with a longer follow-up time frame so that differences between groups over time can 
be detected, as well as the duration of action of PRP on different disease processes and patient 
populations. This would allow for determination of treatment schedules. It is currently unclear 
whether multiple injections improve or worsen outcomes. Follow up should include routine 
radiologic studies to objectively guide this process and determine the extent of anatomical 
improvement of degeneration and injury as compared with baseline imaging. Administration of 
studies meeting these criteria can demonstrate PRP injections to be an affordable, safe alternative 
to current treatment options, in addition to improving the disability status of adults with chronic 
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